Atypical Antipsychotics in Bipolar and Schizoaffective Disorders

No data are available comparing the relative efficacy of different atypical agents in patients with bipolar disorder. A chart review of bipolar and schizoaffective disorder patients who had received courses of at least two atypical agents (n = 33) in a community psychiatry system was conducted. No differences in rates of hospitalizations were found between individual atypical agents or between atypical agents as a class and conventional neuroleptics. However, a significant reduction in rates of emergency room visits was found with atypical agents compared to conventional neuroleptics, with a trend toward greater reduction with clozapine compared to other atypical antipsychotics. Larger prospective studies are needed to confirm these preliminary observations.

References

• 1 Biological Therapies Chapter 33. In: Kaplan HI, Sadock BJ (eds) Synopsis of Psychiatry, 7 th ed. Baltimore; Williams & Wilkins 1994: pg. 956, Table 33.3.17- 7
• 2 Calabrese J R, Kimmel S E, Woyshville M J, Rapport D J, Faust C J, Thompson P A, Meltzer H Y. Clozapine for treatment-refractory mania.  Am J Psychiatry. 1996;  153 759-764
• 3 Markowitz J S, Brown C S, Moore T R. Atypical antipsychotics. Part 1: Pharmacology, pharmacokinetics, and efficacy.  Ann Pharmacother. 1999;  33 73-85
• 4 Segal L, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.  Clin Neuropharmacol. 1998;  21 176-180
• 5 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G, Petty F, Centorrino F, Wang R, Grundy S L, Greaney M G, Jacobs T J, David S R, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.  Am J Psychiatry. 1999;  156 702-709